Clinical Trial Update: A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) [Phase 3]

View source ↗

Summary

Phase 3 trial update for VX-445 combination therapy in cystic fibrosis patients with F508del and a gating or residual function mutation (F/G and F/RF genotypes)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-445

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2021-07-02